RxDoctor Payments Data

Jose Rodriguez Castro, MD

Cardiovascular Disease · Bayamon, PRNPI 1013085554

Payments from drug & device makers

$3,968in general payments, 2019–2025

Across 160 payments — averaging $24.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$684
  • Inari Medical, Inc.$562
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$560
  • Boehringer Ingelheim$461
  • PBG Puerto Rico LLC$364
  • AstraZeneca$343
  • plus $995 from 11 others

What the payments were for

  • Food & beverage$3,962100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,968 in reported general payments places this provider in the 55th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$13,423
Medicare patients
56
Services billed
185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban216$216,565
XareltoRivaroxaban185$214,790
FarxigaDapagliflozin Propanediol100$114,461
Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid410$78,616
JardianceEmpagliflozin45$66,766
BrilintaTicagrelor48$51,848
SynthroidLevothyroxine Sodium275$35,454
EntrestoSacubitril/Valsartan22$26,052
Candesartan Cilexetil151$22,185
Metoprolol Succinate1,090$21,994
JanuviaSitagliptin Phosphate15$16,489
JanumetSitagliptin Phos/Metformin Hcl20$15,074
Nifedipine ErNifedipine390$13,462
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid100$13,443
Rosuvastatin Calcium740$11,750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$6$216,565216 claims
Johnson & JohnsonXarelto$684$214,790185 claims
AstraZenecaFarxiga, Brilinta$343$166,309148 claims
Boehringer IngelheimJardiance$461$66,76645 claims
AbbVieSynthroid$50$35,454275 claims
NovartisEntresto$22$26,05222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in Bayamon

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →